Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

Neurocognitive Benefits of Second-Generation Antipsychotics Versus Placebo: Insufficient Evidence Based on a Systematic Review

Takeuchi, Hiroyoshi MD, PhD; Thiyanavadivel, Sadhana; Fervaha, Gagan PhD; Remington, Gary MD, PhD, FRCPC

Journal of Clinical Psychopharmacology: April 2017 - Volume 37 - Issue 2 - p 274–276
doi: 10.1097/JCP.0000000000000662
Letters to the Editors - Research Reports

Schizophrenia Division, Complex Care & Recovery Program, Centre for Addiction and Mental Health and Department of Psychiatry, University of Toronto, Toronto, Canada and Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan hirotak@dk9.so-net.ne.jp;

Schizophrenia Division, Complex Care & Recovery Program, Centre for Addiction and Mental Health and Department of Anthropology, University of Toronto, Toronto, Canada;

Schizophrenia Division, Complex Care & Recovery Program, Centre for Addiction and Mental Health and Institute of Medical Science, University of Toronto, Toronto, Canada;

Schizophrenia Division, Complex Care & Recovery Program, Centre for Addiction and Mental Health and Department of Psychiatry, University of Toronto and Institute of Medical Science, University of Toronto and Campbell Family Mental, Health Research Institute, Centre for Addiction and Mental Health, Toronto, Canada.

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.